Related Experiment Videos
Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes.
J McMurry1, H Sbai, M L Gennaro
1TB/HIV Research Laboratory, Brown University, Providence, RI 02912, USA.
Tuberculosis (Edinburgh, Scotland)
|February 3, 2005
Summary
Bioinformatics identified potential tuberculosis vaccine epitopes from Mycobacterium tuberculosis secreted proteins. In vitro testing confirmed 15 epitopes, including one highly promiscuous candidate, showing promise for a multi-epitope TB vaccine.
Area of Science:
- Immunology
- Bioinformatics
- Vaccine Development
Background:
- Secreted antigens of Mycobacterium tuberculosis (Mtb) are crucial for T cell responses and interferon-gamma (IFN-gamma) secretion, key components of defense against Mtb.
- Identifying effective vaccine targets requires efficient screening of numerous potential epitopes.
Purpose of the Study:
- To identify and validate novel epitopes from Mtb secreted proteins for potential inclusion in a multi-epitope tuberculosis vaccine.
- To assess the efficacy of bioinformatics tools combined with in vitro assays for epitope discovery.
Main Methods:
- Utilized web-based bioinformatics tools (SignaIP, Prosite) to identify secreted proteins in Mtb genomes.
- Employed EpiMatrix algorithm to predict T cell epitopes with high class II MHC binding motif matches.
- Synthesized and tested 17 top-ranked peptide candidates using peripheral blood mononuclear cells (PBMCs) from Mtb-immune donors.
- Assessed T cell responses via IFN-gamma ELISpot and lymphocyte proliferation assays.
Main Results:
- Bioinformatics screening reduced the number of potential epitopes to 5% of the initial peptide pool.
- 15 out of 17 (88%) synthesized peptides stimulated IFN-gamma response in vitro.
- Eight out of 17 (47%) peptides stimulated lymphocyte proliferation.
- IFN-gamma ELISpot assays demonstrated higher sensitivity for detecting T cell responses compared to proliferation assays.
- A specific epitope (MT2281-26-J) induced IFN-gamma secretion in 44% of Mtb-immune subjects' PBMCs.
- 15 epitopes, notably MT2281-26-J, are strong candidates for a multi-epitope TB vaccine.
Conclusions:
- Bioinformatics tools effectively narrow down potential epitopes for vaccine development.
- In vitro validation confirmed the immunogenicity of several Mtb-derived epitopes.
- IFN-gamma ELISpot is a sensitive method for evaluating T cell responses to vaccine candidates.
- The identified epitopes, particularly MT2281-26-J, represent promising candidates for a novel multi-epitope tuberculosis vaccine.